Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Esophageal Carcinoma Clear all
Completed Phase 3 Interventional Results available

Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer

NCT00052910
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
cisplatin, epirubicin hydrochloride, fluorouracil, leucovorin calcium, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
527
States / cities
Anniston, Alabama • Mobile, Alabama • Scottsdale, Arizona + 357 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Jul 21, 2026, 11:26 AM EDT
Recruiting Phase 1 Interventional

A Study of KK2269 in Adult Participants With Solid Tumors

NCT06266299
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Non Small Cell Lung Cancer
Interventions
KK2269, Docetaxel
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
7
States / cities
Scottsdale, Arizona • Duarte, California • Newport Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 21, 2026, 11:26 AM EDT
Withdrawn Phase 2 Interventional

Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer

NCT03592407
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Epacadostat, Laboratory Biomarker Analysis, Pembrolizumab, Pharmacodynamic Study
Drug · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Duarte, California • South Pasadena, California • West Covina, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Jul 21, 2026, 11:26 AM EDT
Completed Not applicable Interventional

Positron Emission Tomography in Determining Stage of Esophageal Cancer

NCT00004867
View directory record Official record
Conditions
Esophageal Cancer
Interventions
conventional surgery, positron emission tomography, radionuclide imaging, fludeoxyglucose F 18, chemotherapy, Radiotherapy
Procedure · Radiation · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Jul 21, 2026, 11:26 AM EDT
Completed Phase 1 Interventional

Irinotecan and Capecitabine in Treating Patients With Solid Tumors

NCT00003867
View directory record Official record
Conditions
Cancer
Interventions
capecitabine, irinotecan hydrochloride
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Jul 21, 2026, 11:26 AM EDT
Not listed Not applicable Interventional

Non-endoscopic Esophageal Sampling to Detect Barrett's Esophagus and Esophageal Cancer in Veterans

NCT05210049
View directory record Official record
Conditions
Barrett Esophagus, GERD, Obesity, Esophageal Cancer
Interventions
Esocheck/Esoguard
Diagnostic Test
Lead sponsor
Louis Stokes VA Medical Center
Federal
Eligibility
40 Years to 85 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Jul 21, 2026, 11:26 AM EDT
Completed Not applicable Interventional

Computer-Assisted Scheduling of Nicotine Inhaler Use in Participants Who Plan to Stop Smoking

NCT00021138
View directory record Official record
Conditions
Esophageal Cancer, Head and Neck Cancer, Lung Cancer
Interventions
smoking cessation intervention, nicotine
Behavioral · Drug
Lead sponsor
Personal Improvement Computer Systems
Other
Eligibility
18 Years to 67 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Reston, Virginia
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Jul 21, 2026, 11:26 AM EDT
Completed Phase 2 Interventional

Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer

NCT00137852
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Cisplatin, Irinotecan, Celecoxib, Radiation Therapy, Esophagectomy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Jul 21, 2026, 11:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

NCT05070247
View directory record Official record
Conditions
Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
Interventions
TAK-500, Pembrolizumab, Tocilizumab, Dexamethasone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 21, 2026, 11:26 AM EDT
Completed No phase listed Observational

Radiation Therapy and Cardiac Enzymes

NCT00777751
View directory record Official record
Conditions
Tumor
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Jul 21, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Results available

Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma

NCT00447330
View directory record Official record
Conditions
Esophageal Neoplasms, Stomach Neoplasms, Neoplasm Metastasis
Interventions
capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Durham, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Jul 21, 2026, 11:26 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

NCT05366881
View directory record Official record
Conditions
Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
Interventions
Not listed
Lead sponsor
Adela, Inc
Industry
Eligibility
40 Years and older
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
17
States / cities
Duarte, California • Miami, Florida • Gainesville, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jul 21, 2026, 11:26 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

NCT04272034
View directory record Official record
Conditions
Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma, Cyclin-dependent Kinase 12 Mutated Tumors, Basal Cell Carcinoma (Unresectable or Metastatic), Sarcomatoid Renal Cell Carcinoma, Clear Cell Ovarian or Endometrial Carcinoma, Anal Carcinoma, Squamous Cell Penile Carcinoma, DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)
Interventions
INCB099318
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Hackensack, New Jersey • Greenville, South Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Jul 21, 2026, 11:26 AM EDT
Completed Phase 4 Interventional Results available

Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus.

NCT00754468
View directory record Official record
Conditions
Barrett's Esophagus, Esophageal Cancer
Interventions
Cryo Spray Ablation
Device
Lead sponsor
CSA Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Jul 21, 2026, 11:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab

NCT03709706
View directory record Official record
Conditions
Neoplasms
Interventions
Lete-cel, Pembrolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
20
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Jul 21, 2026, 11:26 AM EDT
Completed Not applicable Interventional

Pain Management Smartphone Application for Patients With Stage III-IV Head and Neck Cancer Undergoing Radiation Therapy

NCT02324881
View directory record Official record
Conditions
Head and Neck Cancer, Pain, Lung Cancer, Esophageal Cancer
Interventions
Telephone-Based Intervention, Questionnaire Administration
Behavioral · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Jul 21, 2026, 11:26 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

NCT03430843
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
Tislelizumab, Paclitaxel, Docetaxel, Irinotecan
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Detroit, Michigan • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Jul 21, 2026, 11:26 AM EDT
Completed No phase listed Observational

Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer

NCT00836992
View directory record Official record
Conditions
Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Jul 21, 2026, 11:26 AM EDT
Active, not recruiting Phase 1 Interventional

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

NCT05075993
View directory record Official record
Conditions
Metastatic Esophageal, Gastric Cancer, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic HPV Related Solid Tumors, Metastatic Ovarian Carcinoma, Metastatic Soft Tissue Sarcoma, Metastatic Uveal Melanoma
Interventions
LVGN3616 + LVGN6051 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide, LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 21, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

NCT03261947
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, Colorectal Cancer, Esophageal Neoplasms, Carcinoma, Non-small-cell Lung
Interventions
TAK-931
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
8
States / cities
Denver, Colorado • Sarasota, Florida • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Jul 21, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Results available

Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors

NCT00515216
View directory record Official record
Conditions
Stomach Neoplasms, Esophageal Neoplasms
Interventions
5-fluorouracil, Oxaliplatin, Leucovorin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
4
States / cities
Birmingham, Alabama • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Jul 21, 2026, 11:26 AM EDT
Recruiting Phase 2 Interventional

PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer

NCT06906887
View directory record Official record
Conditions
Esophageal Cancer, Oesophageal Cancer, GastroEsophageal Cancer
Interventions
Induction Chemotherapy (modified FLOT or modified FOLFOX-6), Chemotherapy, Conventional Radiation, Pulsed Low-Dose-Rate (PLDR) Radiation, Surgery
Drug · Radiation · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Jul 21, 2026, 11:26 AM EDT
Completed Phase 2 Interventional

Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer

NCT00165464
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer, GE Junction Cancer
Interventions
Taxotere, Cisplatin, Irinotecan
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2009 · Synced Jul 21, 2026, 11:26 AM EDT
Recruiting Phase 1 Interventional

A Study of MGC026 in Participants With Advanced Solid Tumors

NCT06242470
View directory record Official record
Conditions
Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer, Breast Cancer, Ovarian Cancer, Esophageal Squamous Cell Cancer (SCC)
Interventions
MGC026 Dose Escalation, MGC026 Dose for Expansion
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Los Angeles, California • Grand Rapids, Michigan • Lake Success, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 21, 2026, 11:26 AM EDT